CN104395290A - 作为大麻素受体2激动剂的新金刚烷基衍生物 - Google Patents
作为大麻素受体2激动剂的新金刚烷基衍生物 Download PDFInfo
- Publication number
- CN104395290A CN104395290A CN201380034653.5A CN201380034653A CN104395290A CN 104395290 A CN104395290 A CN 104395290A CN 201380034653 A CN201380034653 A CN 201380034653A CN 104395290 A CN104395290 A CN 104395290A
- Authority
- CN
- China
- Prior art keywords
- base
- diamantane
- dihydro
- ketone
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(CCC1)CC1(*)C(*)C1*C1 Chemical compound CC(CCC1)CC1(*)C(*)C1*C1 0.000 description 5
- LNALAEMUZYFZBX-UHFFFAOYSA-N CC(CC(C1)(C2)C1C1)CC21C(N(CC1)c2ccccc2C1C(NC(C)(C)C)=O)=O Chemical compound CC(CC(C1)(C2)C1C1)CC21C(N(CC1)c2ccccc2C1C(NC(C)(C)C)=O)=O LNALAEMUZYFZBX-UHFFFAOYSA-N 0.000 description 1
- YHHCORFIQWUSMH-IBUVBVCCSA-N C[C@](C1)(C2)C1=C(C1)C(C3)[C@@H]1CC23C(N1c2cccc(C(OC)=O)c2CC1)=O Chemical compound C[C@](C1)(C2)C1=C(C1)C(C3)[C@@H]1CC23C(N1c2cccc(C(OC)=O)c2CC1)=O YHHCORFIQWUSMH-IBUVBVCCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12174968.3 | 2012-07-04 | ||
EP12174968 | 2012-07-04 | ||
PCT/EP2013/063773 WO2014005968A1 (en) | 2012-07-04 | 2013-07-01 | Novel adamantyl derivatives as cannabinoid receptor 2 agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104395290A true CN104395290A (zh) | 2015-03-04 |
Family
ID=48703559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380034653.5A Pending CN104395290A (zh) | 2012-07-04 | 2013-07-01 | 作为大麻素受体2激动剂的新金刚烷基衍生物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9090615B2 (pt) |
EP (1) | EP2870139B1 (pt) |
JP (1) | JP2015521652A (pt) |
KR (1) | KR20150027824A (pt) |
CN (1) | CN104395290A (pt) |
BR (1) | BR112014032996A2 (pt) |
CA (1) | CA2876443A1 (pt) |
HK (1) | HK1202546A1 (pt) |
MX (1) | MX2014015491A (pt) |
RU (1) | RU2015101818A (pt) |
WO (1) | WO2014005968A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2964646T1 (sl) | 2013-03-07 | 2017-08-31 | F. Hoffmann-La Roche Ag | Novi derivati pirazola |
JP6500010B2 (ja) | 2013-03-26 | 2019-04-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 新規ピリジン誘導体 |
DK2991988T3 (en) | 2013-05-02 | 2017-08-21 | Hoffmann La Roche | Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists |
JP6513636B2 (ja) | 2013-05-02 | 2019-05-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Cb2受容体アゴニストとしてのプリン誘導体 |
ES2714094T3 (es) | 2013-09-06 | 2019-05-27 | Hoffmann La Roche | Derivados de triazolo[4,5-d]pirimidina como antagonistas del receptor cb2 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2172453A1 (en) * | 2007-06-27 | 2010-04-07 | Taisho Pharmaceutical Co. Ltd. | COMPOUND HAVING 11 ß-HSD1 INHIBITORY ACTIVITY |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8471026B2 (en) * | 2010-08-26 | 2013-06-25 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
-
2013
- 2013-07-01 WO PCT/EP2013/063773 patent/WO2014005968A1/en active Application Filing
- 2013-07-01 JP JP2015519157A patent/JP2015521652A/ja active Pending
- 2013-07-01 BR BR112014032996A patent/BR112014032996A2/pt not_active IP Right Cessation
- 2013-07-01 RU RU2015101818A patent/RU2015101818A/ru unknown
- 2013-07-01 CN CN201380034653.5A patent/CN104395290A/zh active Pending
- 2013-07-01 EP EP13732543.7A patent/EP2870139B1/en not_active Not-in-force
- 2013-07-01 CA CA 2876443 patent/CA2876443A1/en not_active Abandoned
- 2013-07-01 KR KR20157002874A patent/KR20150027824A/ko not_active Application Discontinuation
- 2013-07-01 MX MX2014015491A patent/MX2014015491A/es unknown
-
2014
- 2014-12-22 US US14/578,935 patent/US9090615B2/en not_active Expired - Fee Related
-
2015
- 2015-03-31 HK HK15103218.3A patent/HK1202546A1/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2172453A1 (en) * | 2007-06-27 | 2010-04-07 | Taisho Pharmaceutical Co. Ltd. | COMPOUND HAVING 11 ß-HSD1 INHIBITORY ACTIVITY |
Non-Patent Citations (3)
Title |
---|
REGISTRY: "RN883841-97-2", 《STN COLUMBUS》, 11 May 2006 (2006-05-11) * |
SCOTT P. WEBSTER, ET AL.: "Discovery and biological evaluation of adamantyl amide 11b-HSD1 inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, no. 17, 31 December 2007 (2007-12-31), pages 2838 - 2843 * |
SIMONE BROGI,ET AL.: "Three-dimensional quantitative structureeselectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, no. 46, 31 December 2011 (2011-12-31), pages 547 - 555 * |
Also Published As
Publication number | Publication date |
---|---|
JP2015521652A (ja) | 2015-07-30 |
BR112014032996A2 (pt) | 2018-05-15 |
EP2870139B1 (en) | 2016-06-15 |
HK1202546A1 (en) | 2015-10-02 |
WO2014005968A1 (en) | 2014-01-09 |
MX2014015491A (es) | 2015-03-06 |
US9090615B2 (en) | 2015-07-28 |
EP2870139A1 (en) | 2015-05-13 |
KR20150027824A (ko) | 2015-03-12 |
RU2015101818A (ru) | 2016-08-27 |
US20150111886A1 (en) | 2015-04-23 |
CA2876443A1 (en) | 2014-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6321045B2 (ja) | キナーゼ阻害剤としての複素環式アミド | |
Ishida et al. | Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling | |
CN103965120B (zh) | 喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用 | |
DK2401267T3 (en) | JAK-kinase modulating quinazoline derivatives AND THEIR APPLICATION IN PROCESSES | |
CN104039791B (zh) | 作为大麻素受体2激动剂的[1,2,3]三唑并[4,5-d]嘧啶衍生物 | |
CN104395290A (zh) | 作为大麻素受体2激动剂的新金刚烷基衍生物 | |
CN103930426A (zh) | 作为大麻素受体2激动剂的[1,2,3]三唑并[4,5-d]嘧啶衍生物 | |
CN1980934B (zh) | 作为选择性雄激素受体调节剂(sarms)的新的吲哚衍生物 | |
SA05260409B1 (ar) | مثبطات جديده لانزيمات البروتينات المعدنية لهيدانتوين | |
CN105164133A (zh) | 作为CB2受体激动剂的吡咯并[2,3-d]嘧啶衍生物 | |
CN100369919C (zh) | 三环蛋白激酶抑制剂 | |
WO2012030944A2 (en) | Quinoline and isoquinoline compounds and methods of use thereof | |
CA2901267C (en) | Novel n-(2,3-dihydro-1h-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and n-(2,3-dihydro-1h-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors | |
CN105209466A (zh) | 作为cb2受体激动剂的嘌呤衍生物 | |
US20120053176A1 (en) | Adenosine a3 receptor modulating compounds and methods of use thereof | |
CN104837830A (zh) | 作为cb2受体激动剂的新的吡嗪衍生物 | |
CN101270110B (zh) | 磺酰基取代的氧杂蒽酮类化合物及其制备方法与应用 | |
Zhao et al. | Design, synthesis and evaluation of novel 5-phenylpyridin-2 (1H)-one derivatives as potent reversible Bruton’s tyrosine kinase inhibitors | |
EP3369733B1 (en) | Crystal form of 4h-pyrazolo[1,5- ]benzoimidazole compound, preparation method therefor and intermediate thereof | |
CN105283452A (zh) | 新的四唑酮衍生物 | |
Kinoyama et al. | (+)-(2R, 5S)-4-[4-cyano-3-(trifluoromethyl) phenyl]-2, 5-dimethyl-N-[6-(trifluoromethyl) pyridin-3-yl] piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist | |
CZ9394A3 (en) | 9H-IMIDAZO/1,2-a/BENZIMIDAZOL-3-ACETAMIDO DERIVATIVES, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS IN WHICH THEY ARE COMPRISED | |
Nakagawa et al. | Progesterone receptor antagonists with a 3-phenylquinazoline-2, 4-dione/2-phenylisoquinoline-1, 3-dione skeleton | |
Letellier et al. | Synthesis of potential Rho-kinase inhibitors based on the chemistry of an original heterocycle: 4, 4-dimethyl-3, 4-dihydro-1H-quinolin-2-one | |
CN102171191A (zh) | 吲唑衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1202546 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150304 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1202546 Country of ref document: HK |